| MR编号 | SE/H/1986/001 |
|---|
| 药品名称 | Lecigon |
|---|
| 活性成分 | - Carbidopa monohydrate 5.0 mg/ml
- Entacapone 20.0 mg/ml
- Levodopa 20.0 mg/ml
|
|---|
| 剂型 | Intestinal gel |
|---|
| 上市许可持有人 | LobSor Pharmaceuticals AB,
Sweden |
|---|
| 参考成员国 - 产品名称 | Sweden (SE) |
|---|
| 互认成员国 - 产品名称 | - Denmark (DK)
- Norway (NO)
- Finland (FI)
- Slovakia (SK)
- Bulgaria (BG)
- Spain (ES)
- Croatia (HR)
- Czechia (CZ)
Lecigon - France (FR)
- Hungary (HU)
Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intesztinális gél - Italy (IT)
- Ireland (IE)
- Belgium (BE)
Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml gel voor intestinaal gebruik - Austria (AT)
- Germany (DE)
Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml Gel zur intestinalen Anwendung - Netherlands (NL)
Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml gel voor intestinaal gebruik - Romania (RO)
Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinal gel - Slovenia (SI)
- Luxembourg (LU)
- Poland (PL)
Lecigon - Portugal (PT)
|
|---|
| 许可日期 | 2019/09/24 |
|---|
| 最近更新日期 | 2025/01/08 |
|---|
| 药物ATC编码 | - N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor
| 申请类型 | - TypeLevel1：Known Active Substance
- TypeLevel2：Repeat Use
- TypeLevel3：Full Dossier Art 8.3(i) Dir 2001/83/EC
- TypeLevel4：Chemical Substance
- TypeLevel5：Prescription Only
|
|---|
| 附件文件下载 | |
|---|
| 市场状态 | Positive |
|---|
|
|---|